Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Association of RASGRP1 Polymorphism with Vascular Complications in Chinese Diabetic Patients with Glycemic Control and Antihypertensive Treatment
47 Pages Posted: 26 Jun 2020
More...Abstract
Background: Studies have shown that RASGRP1 was strongly associated with the onset of type 2 diabetes, and RASGRP1 rs7403531 was significantly correlated with islet function in type 2 diabetes (T2DM) patients. However, the effect of RASGRP1 polymorphism on blood glucose and blood pressure in T2DM patients after continuous treatment is still unclear.
Methods: We retrospectively analyzed a large multicenter drug clinical study cohort that based on a 2×2 factorial (glucose control axis and blood pressure lowering axis) randomized controlled design, and follow-up for 5 years. The major vascular endpoint events in our study included cardiovascular death, non-fatal stroke, coronary heart disease, new or worsening kidney disease, and diabetic retinopathy. Mixed linear model and Cox hazard ratio model were used for data analysis with SPSS.
Findings: A total of 1357 patients were included in our research with an average follow-up time of 4.8 years. RASGRP1 rs7403531 T allele could reduce the risk of major microvascular events (HR=0.41, 55%CI 0.21-0.80, P =0.009) and major eye diseases(HR=0.44, 95% CI 0.20-0.94, P =0.03) in T2DM patients . In the group based on antihypertensive therapy, active antihypertensive therapy for CC patients reduced the risk of all cerebrovascular events (placebo vs. antihypertensive: HR=2.35, 95% CI 1.06-5.12, P =0.035). For RASGRP1 (rs56254815), compared with the AA genotype carriers, the SBP of AG/GG carriers in the hypotensive group decreased by 1.5mmhg on average ( P =0.04). In the placebo group, the blood pressure of AG/GG carriers was 1.7mmHg higher than that of AA carriers ( P =0.02).
Interpretation: Our findings suggest that RASGRP1 genetic polymorphism might predict the cardiovascular complications in T2DM patients.
Trial Registration: (Registration number NCT00145925).
Funding Statement: Supported by the National Natural Science Foundation of China (NSFC, No 81573511, 81874329, 81522048), the National Key R&D Plan of China (No. 2016YFC0905000).
Declaration of Interests: All authors declare no conflict of interest relevant to the subject matter or materials discussed in the article.
Ethics Approval Statement: Approval to conduct the trial was obtained from the ethics committee of each study center, and all participants provided written informed consent.
Keywords: RASGRP1; polymorphism; Vascular Complications; type 2 diabetes; individual drug treatment
Suggested Citation: Suggested Citation